These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18501306)

  • 21. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).
    Kirby RS; Fitzpatrick JM; Irani J
    BJU Int; 2009 Feb; 103(4):441-5. PubMed ID: 19154510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial comment.
    Chong KT
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683273
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment.
    Lin CC
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683264
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial comment.
    van Renterghem KM
    J Urol; 2009 Oct; 182(4):1349; discussion 1349. PubMed ID: 19683263
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue.
    Brimo F; Vollmer RT; Corcos J; Kotar K; Bégin LR; Humphrey PA; Bismar TA
    Histopathology; 2008 Aug; 53(2):177-83. PubMed ID: 18752501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
    Etzioni RD; Ankerst DP; Thompson IM
    J Natl Cancer Inst; 2007 Mar; 99(6):489-90; author reply 490. PubMed ID: 17374841
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 29. The prognostic value of tumour measurements in prostate needle core biopsy specimens.
    López JI
    Histopathology; 2009 Feb; 54(3):374. PubMed ID: 19236515
    [No Abstract]   [Full Text] [Related]  

  • 30. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anterior apical biopsy: is it useful for prostate cancer detection?
    Orikasa K; Ito A; Ishidoya S; Saito S; Endo M; Arai Y
    Int J Urol; 2008 Oct; 15(10):900-4; discussion 904. PubMed ID: 18657203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
    Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving cancer detection by prostate biopsy: the role of core number and site.
    Shinohara K
    Nat Clin Pract Urol; 2006 Oct; 3(10):526-7. PubMed ID: 17031375
    [No Abstract]   [Full Text] [Related]  

  • 35. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Rittmaster R
    Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
    [No Abstract]   [Full Text] [Related]  

  • 36. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
    J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial comment on: Improved accuracy in predicting the presence of gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy.
    Remzi M
    Eur Urol; 2007 Dec; 52(6):1668-9. PubMed ID: 17240039
    [No Abstract]   [Full Text] [Related]  

  • 38. Technical considerations when obtaining and interpreting prostatic biopsies from men with a suspicion of early prostate cancer.
    Bott SR; Henderson A; Laing RW; Montgomery BS; Langley SE
    BJU Int; 2005 Sep; 96(4):686. PubMed ID: 16104936
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment.
    Schilling D; Stenzl A
    J Urol; 2010 Feb; 183(2):527-8; discussion 528. PubMed ID: 20006885
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Shariat SF; Svatek RS
    Eur Urol; 2009 Mar; 55(3):626-8. PubMed ID: 18499336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.